Literature DB >> 11451042

Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist.

A Dalpiaz1, A Scatturin, E Menegatti, F Bortolotti, B Pavan, C Biondi, E Durini, S Manfredini.   

Abstract

PURPOSE: A series of 5'-esters of N6-cyclopentyladenosine (CPA) were prepared with the aim to improve stability and bioavailability of selective A1 agonists. Log P values, stability, affinity, and activity toward human adenosine A1 receptors were evaluated.
METHODS: An appropriate synthetic procedure was adopted to avoid concomitant deamination at position 6. Log P values were obtained by the Mixxor system. The stability of CPA and its 5'-ester was evaluated in human plasma and whole blood and analyzed with high-performance liquid chromatography. The affinities to human A1 receptor expressed by N6-cyclohexyladenosine cells were obtained by binding experiments. The activities were evaluated by measurements of the inhibition of forskolin stimulated 3'-5'-cyclic adenosine monophosphate, performing competitive binding assays.
RESULTS: All prodrugs were more lipophilic than CPA, and their hydrolysis, in whole blood and in plasma, was found related, respectively, to the length and hindrance of 5'-substituents. Affinity and activity values indicated a very weak interaction toward adenosine A1 receptor of the intact prodrugs.
CONCLUSIONS: We propose 5'-esters of CPA, characterized by suitable lipophilicity and elevated degree of stability in physiological fluids, as possible candidates for CPA prodrugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451042     DOI: 10.1023/a:1011018730459

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action.

Authors:  M S Brodie; K Lee; B B Fredholm; L Ståhle; T V Dunwiddie
Journal:  Brain Res       Date:  1987-07-14       Impact factor: 3.252

2.  Saturation assay for cyclic AMP using endogenous binding protein.

Authors:  B L Brown; R P Ekins; J D Albano
Journal:  Adv Cyclic Nucleotide Res       Date:  1972

Review 3.  Cardiac electrophysiology and pharmacology of adenosine: basic and clinical aspects.

Authors:  A Pelleg; L Belardinelli
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

4.  Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors.

Authors:  A Dalpiaz; A Townsend-Nicholson; M W Beukers; P R Schofield; A P IJzerman
Journal:  Biochem Pharmacol       Date:  1998-12-01       Impact factor: 5.858

5.  Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning.

Authors:  C Heurteaux; I Lauritzen; C Widmann; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding.

Authors:  A Townsend-Nicholson; P R Schofield
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

7.  Processing of adenosine receptor agonists in rat and human whole blood.

Authors:  B Pavan; A P IJzerman
Journal:  Biochem Pharmacol       Date:  1998-12-15       Impact factor: 5.858

8.  Molecular cloning and characterisation of a human brain A1 adenosine receptor cDNA.

Authors:  A Townsend-Nicholson; J Shine
Journal:  Brain Res Mol Brain Res       Date:  1992-12

9.  Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists.

Authors:  R E Simpson; M H O'Regan; L M Perkins; J W Phillis
Journal:  J Neurochem       Date:  1992-05       Impact factor: 5.372

10.  Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.

Authors:  R A Mathôt; E A van Schaick; M W Langemeijer; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

View more
  3 in total

1.  A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.

Authors:  Kenneth A Jacobson; Michihiro Ohno; Heng T Duong; Soo-Kyung Kim; Susanna Tchilibon; Michal Cesnek; Antonín Holý; Zhan-Guo Gao
Journal:  Chem Biol       Date:  2005-02

2.  AMP is an adenosine A1 receptor agonist.

Authors:  Joseph E Rittiner; Ilia Korboukh; Emily A Hull-Ryde; Jian Jin; William P Janzen; Stephen V Frye; Mark J Zylka
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

Review 3.  Progress in drug delivery to the central nervous system by the prodrug approach.

Authors:  Barbara Pavan; Alessandro Dalpiaz; Nunzia Ciliberti; Carla Biondi; Stefano Manfredini; Silvia Vertuani
Journal:  Molecules       Date:  2008-05-01       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.